We’re looking forward to presenting at Needham’s upcoming Virtual Healthcare Conference. Tune in on Monday, April 8 at 8:45am ET to hear our CEO, Alex Martin, discuss our company, mission, and work in #InclusionBodyMyositis. #IBM #Biotech #Autoimmune

We are taking May, #MyositisAwarenessMonth, to recognize the estimated 54,000 people affected by #InclusionBodyMyositis, a chronic, progressive muscle disease with no approved therapies. #IBM The Myositis Association

We believe ulviprubart, our investigational product candidate currently in clinical trials, represents a novel approach to selective depletion of the highly cytotoxic T cells that attack the muscles in #IBM. Learn more: abcuro.com/science/ #MyositisAwarenessMonth

We are pleased to share that we have completed enrollment in our registrational Phase 2/3 MUSCLE clinical trial of ulviprubart (ABC008), our investigational product candidate for the treatment of #InclusionBodyMyositis. Learn more: businesswire.com/news/home/2024… #ClinicalTrials #IBM

We are pleased to share that Sarah Boyce, a seasoned leader with years of commercial and clinical development expertise, is joining our Board of Directors. We look forward to her guidance as we work to advance ulviprubart (ABC008), our investigational product candidate, in #IBM.

Our CEO Alex Martin is looking forward to discussing Abcuro and our work in #InclusionBodyMyositis at fall investor conferences including Morgan Stanley and Stifel. #IBM #autoimmune #clinicaltrials

CEO Alex Martin will be in New York next week for the Oppenheimer & Co. Inc. Private Life Sciences Company Showcase. If you’re attending, check out his presentation at 10:35am ET on October 1st to learn more about Abcuro and our work in #InclusionBodyMyositis. #IBM #autoimmune #biotech

Dive into Abcuro and our work to better the lives of patients with T cell driven autoimmune disease, including #IBM with our CEO Alex Martin and host Rahul Chaturvedi on the latest episode of the Biotech2050 Podcast podcast. Rahul Chaturvedi Listen below! bit.ly/3YqnqmG

If you’re attending the upcoming Stifel or Piper Sandler Healthcare Conferences, come watch CEO Alex Martin’s presentations for a deep dive on Abcuro and our ongoing work in #InclusionBodyMyositis. #IBM #autoimmune #clinicaltrials #biotech

We are excited to share that Abcuro has been selected as one of Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2024! We are honored to be recognized for our work in #InclusionBodyMyositis and want to extend a special thank you to our dedicated team.

Abcuro CEO Alex Martin participated in a muscle disease panel at the Piper Sandler Healthcare Conference this week to discuss our work in #InclusionBodyMyositis, and the current treatment landscape.

Happy New Year! As we reflect on 2024, we wanted to say thank you to our team for their dedication in helping us to advance ulviprubart (ABC008), our investigational product candidate, for those living with #IBM. We look forward to what we can accomplish together in 2025.

Congratulations to our CEO Alex Martin, who was named one of Healthcare Technology Report’s Top 50 Healthcare CEOs of 2024! Read more: thehealthcaretechnologyreport.com/the-top-50-hea… #biotech #leadership

Our COO, Karen Tubridy, was named one of Healthcare Technology Report’s Top 50 Women Leaders in Healthcare Technology. This recognition is a testament to her leadership and the important role she plays at Abcuro. Congratulations, Karen! Read more: thehealthcaretechnologyreport.com/the-top-50-wom…

This morning, we were pleased to announce that we closed a $200 million Series C with support from new and existing investors to help further our work in #IBM. Read more: abcuro.com/uncategorized/… #InclusionBodyMyositis #autoimmune #biotech

As we advance our work in #InclusionBodyMyositis we are taking time today to recognize those living with #IBM and their caregivers who inspire our work to solve for this #raredisease. Learn more about our clinical trials: abcuro.com/clinical-trial… #RareDiseaseDay

We’ll be at the American Academy of Neurology 2025 Annual Meeting presenting data from our Phase 1 clinical trial of ulviprubart (ABC008) in #InclusionBodyMyositis and epidemiological and diagnostic data on the patient journey with #IBM. Read more: abcuro.com/uncategorized/… #AANAM

We’re looking forward to the 24th Annual Needham Virtual Healthcare Conference where our CEO Alex Martin will be presenting at 10:15am ET on Tuesday, April 8th. If you’re attending, tune in to learn more about Abcuro and our work in #InclusionBodyMyositis. #autoimmune #IBM

Our COO, Karen Tubridy, participated in a panel at World Orphan Drug Congress USA on women redefining healthcare, discussing topics including overcoming barriers in the healthcare industry and creating impactful solutions in rare diseases. #WorldOrphanUSA

This #MyositisAwarenessMonth, and every month, we’re committed to help raise awareness for those living with myositis including #IBM, a rare, devastating, progressive disease with no available disease modifying treatment options. Our work in IBM: abcuro.com/pipeline/#IBM